I think that’s because neurologists are learning more and more about Covid-19 and various MS medications. Early data shows that MS patients seems to be underrepresented in the ICU. Rheumatologists seems to use Mabtherasom as usual.

I recently received Rituximab (biosimilar to Mabthera) and do not feel the least bit worried after about increased risk for severe Covid-19.

But … feel free to ask COMBAT-MS. Because I’m very curious about what they say.